Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Cureus ; 16(4): e58067, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38738100

RESUMO

Uterine smooth muscle tumors of undetermined malignant potential (STUMPs) are an uncommon kind of uterine smooth muscle tumor. It is distinguished by histopathologic and morphologic characteristics that are in between those of a benign leiomyoma and a malignant leiomyosarcoma. From a clinical standpoint, the clinical presentation of STUMP is similar to that of a fibroid. The diagnosis is usually confirmed after surgery. Here, we report the case of a 39-year-old woman who experienced increased menorrhagia, back pain, and pressure sensations during the past six months. She had a well-defined, freely movable lump in her lower abdomen, measuring the size of a 22-cm uterus. The patient exhibited pallor, and her imaging scan showed the presence of an intramural posterior uterine solid mass indistinguishable from fibroid measuring 8.5 × 9 cm. Goserelin acetate (Zoladex 3.6 mg implant) was recommended for a duration of six months. The patient experienced a significant amelioration in menorrhagia and discomfort. However, no reduction in the size of the mass was observed. Myomectomy was made for the suspicion of a malignant transformation. The histology examination confirmed the diagnosis of a STUMP; a hysterectomy was undergone, and the procedure went smoothly. The patient was discharged home in good condition with instructions for long-term follow-up due to a risk of recurrence of about 7%. The lack of standardized and clear clinical and diagnostic criteria for STUMP adds challenges to their management.

2.
Artigo em Inglês | MEDLINE | ID: mdl-38765541

RESUMO

Objective: The aims of the study are to describe the association of coronavirus disease (COVID-19) with the abnormal histopathological findings in human placenta and to highlight the potential predictors of these histopathological findings. Methods: A retrospective cohort study, held in two obstetric units from January 2021- 2022, 34 patients who were confirmed cases of COVID- 19 were followed up till the time of delivery as their placenta were sent for histopathology. Patients diagnosed with other viral infections, chorioamnionitis, or were known case of as pre-term or term pre labour rupture of membrans (PROM) were excluded as well as pre exisiting diabetes mellitus or pre-eclampsia. Data analysis were performed using STATA software version 16. Result: Specific histopatological findings (fetal vascular malperfusion, maternal vascular malperfusion, inflammatory pathology and thrombotic finding) were significantly high among 13 (38.2%) of the study group who got infected earlier in pregnancy (P<0.001). The period between the diagnosis of COVID-19 and the delivery significantly increases the odds of the presence of pathological findings by 2.75 times for each week the patients getting infected earlier. Conclusion: Association of abnormal placental histopathological findings with COVID-19 infection in pregnancy and the potential predictor for the occurrence of placental findings is the longer duration between the diagnosis of the infection and the delivery.


Assuntos
COVID-19 , Placenta , Complicações Infecciosas na Gravidez , Humanos , Feminino , Gravidez , Estudos Retrospectivos , COVID-19/patologia , COVID-19/complicações , Placenta/patologia , Adulto , Complicações Infecciosas na Gravidez/patologia , SARS-CoV-2 , Doenças Placentárias/patologia , Estudos de Coortes
3.
Rev. bras. ginecol. obstet ; 46: e, 2024. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1559558

RESUMO

Abstract Objective: The aims of the study are to describe the association of coronavirus disease (COVID-19) with the abnormal histopathological findings in human placenta and to highlight the potential predictors of these histopathological findings. Methods: A retrospective cohort study, held in two obstetric units from January 2021- 2022, 34 patients who were confirmed cases of COVID- 19 were followed up till the time of delivery as their placenta were sent for histopathology. Patients diagnosed with other viral infections, chorioamnionitis, or were known case of as pre-term or term pre labour rupture of membrans (PROM) were excluded as well as pre exisiting diabetes mellitus or pre-eclampsia. Data analysis were performed using STATA software version 16. Result: Specific histopatological findings (fetal vascular malperfusion, maternal vascular malperfusion, inflammatory pathology and thrombotic finding) were significantly high among 13 (38.2%) of the study group who got infected earlier in pregnancy (P<0.001). The period between the diagnosis of COVID-19 and the delivery significantly increases the odds of the presence of pathological findings by 2.75 times for each week the patients getting infected earlier. Conclusion: Association of abnormal placental histopathological findings with COVID-19 infection in pregnancy and the potential predictor for the occurrence of placental findings is the longer duration between the diagnosis of the infection and the delivery.

4.
J Clin Med ; 12(23)2023 Nov 21.
Artigo em Inglês | MEDLINE | ID: mdl-38068274

RESUMO

Childbirth is a remarkable, life-changing process and is frequently regarded as an excruciating, physically and emotionally demanding experience that women endure. Labor pain management poses a significant challenge for obstetricians and expectant mothers. Although pharmacological pain management is the gold standard, it still imposes risks on the mother and baby. Recently, non-pharmacological pain management (NPPM) has emerged as a safe, effective option. Six databases were searched for articles published up to 2023 using specific related keywords and defined inclusion and exclusion criteria. The extraction and gathering of data was made so as to be categorized into physical, psychological, and complementary NPPM techniques. In light of the enormous development and diversity of NPPM techniques, the present review aims to examine contemporary NPPM knowledge and application, discussing efficacy, advantages, limitations, and potential adverse effects, with a specific focus on women's individual requirements, to strengthen obstetricians' knowledge in guiding decision-making for women in childbirth.

5.
Obstet Gynecol Sci ; 66(5): 430-440, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37473783

RESUMO

OBJECTIVE: Oxidative stress (OS) occurs when excess free radicals damage the DNA. Moreover, 8-oxo-2'-deoxyguanosine (8-OHdG) is a well-known biomarker for OS linked to cellular damage and gene instability. However, its role in female subfertility has not been properly assessed. We aimed to examine the level of OS represented by 8-OHdG based on the cause of subfertility and to test its correlation with reproductive hormones, intracytoplasmic sperm injection (ICSI) parameters, and outcomes. METHODS: A cross-sectional study examined 108 subfertile couples with endometriosis, polycystic ovary syndrome (PCOS), tubal factors, and unexplained infertility undergoing ICSI treatment with two different stimulation programs. We included couples whose partners had normal sperm parameters. Levels of follicular fluid (FF) 8-OHdG were correlated with the causes of subfertility and fertilization rates and compared between pregnant and non-pregnant cases. RESULTS: Based on the causes of subfertility, FF 8-OHdG was the highest among endometriosis cases, followed by PCOS cases. Furthermore, FF 8-OHdG was higher in non-pregnant (2.37±0.75 ng/mL) vs. pregnant (1.58±0.39 ng/mL), P<0.001. A two-way analysis of variance showed that only subfertility affected ICSI outcomes, whereas the stimulation program did not. FF 8-OHdG correlated positively with female age and inversely with estradiol and good-quality embryos. The receiver operating characteristic estimated 8-OHdG cutoff value of 1.8 ng/mL predicted clinical pregnancies with 86.7% sensitivity and 74.4% specificity (P<0.001). CONCLUSION: Higher FF 8-OHdG levels negatively impacted ICSI outcomes. FF 8-OHdG discriminated between cases of clinical pregnancy with good specificity and sensitivity. Because OS can be measured and treated, this opens up a therapeutic and prognostic avenue for improving ICSI outcomes.

6.
Rev. bras. ginecol. obstet ; 44(9): 854-865, Sept. 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1423283

RESUMO

Abstract Objective To comparatively evaluate the outcome of treatment with 150 versus 200 units (U) of botulinum toxin in achieving pain-free intercourse and relieving muscle contraction in order to allow gynecological examination. Methods In this comparative prospective observational study, 99 patients with vaginismus were treated with botulinum toxin injections from September 2016 to August 2021. Diagnosis and grading of vaginismus severity were assessed using a Female Sexual Function Index (FSFI) questionnaire. Under local or general anesthesia, botulinum toxin diluted with preservative-free saline (150 U and 200 U) was injected into, above, and below the right and left bulbospongiosus muscle and the lateral submucosal areas of the introitus and perineal body using an insulin syringe. Patients were recalled after 2 weeks, and the postoperative outcome was recorded using a similar preoperative questionnaire. Results Overall, the mean age of patients was 30.2 years. The baseline and clinical characteristics were comparable between the 2 groups (p > 0.05). Significant improvements were seen in the pain and anxiety scores of finger penetration, dilator use, intercourse, and cotton swab in individual groups. The intergroup comparisons between 150 U and 200 U of Botox were not statistically significant (p > 0.05). Conclusion Low-dose Botox (150 U) is equally effective as high dose Botox injections (200 U) in vaginismus patients. Therefore, Botox-150 U can be used to treat vaginismus as an alternative to high doses of the same substance.


Resumo Objetivo Avaliar comparativamente o resultado do tratamento com 150 versus 200 unidades (U) de toxina botulínica na obtenção de relações sexuais sem dor e no alívio da contração muscular para permitir o exame ginecológico. Métodos Neste estudo observacional prospectivo comparativo, 99 pacientes com vaginismo foram tratadas com injeções de toxina botulínica de setembro de 2016 a agosto de 2021. O diagnóstico e a classificação da gravidade do vaginismo foram avaliados usando um questionário Female Sexual Function Index (FSFI). Sob anestesia local ou geral, injetou-se toxina botulínica diluída em soro fisiológico sem conservantes (150 U e 200 U) nos músculos bulbo esponjoso direito e esquerdo e nas áreas submucosas laterais do intróito e corpo perineal, utilizando-se uma seringa de insulina. Os pacientes foram chamados após 2 semanas, e o resultado pós-operatório foi registrado usando um questionário pré-operatório semelhante. Resultados No geral, a média de idade dos pacientes foi de 30,2 anos. As características basais e clínicas foram comparáveis entre os 2 grupos (p > 0,05). Melhorias significativas foram observadas nos escores de dor e ansiedade à penetração com dedo, uso de dilatador, relação sexual e cotonete em grupos individuais. As comparações intergrupos entre 150 U e 200 U Botox foram não estatisticamente significativas (p > 0,05). Conclusão Botox de baixa dose (150 U) é tão eficaz quanto injeções de Botox de alta dose (200 U) em pacientes com vaginismo. Portanto, o Botox-150 U pode ser usado para tratar o vaginismo como alternativa às altas doses da mesma substância.


Assuntos
Humanos , Feminino , Ansiedade , Dor/tratamento farmacológico , Toxinas Botulínicas , Vaginismo
7.
J Obstet Gynaecol India ; 72(Suppl 1): 290-294, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35928074

RESUMO

Background: Physiologically, the spermatozoa are exposed to reactive oxygen species (ROS), and those ROS can strongly affect sperm's function through sperm capacitation. However, producing a high level of ROS reduces the sperm anti-oxidation system that may cause infertility, especially in cases with normal sperm count. Purpose: To investigate the expression of the CYP24A1 gene in human spermatozoa and other oxidation-related biomarkers, including vitamin E, ROS, and catalase as added tools to predict male infertility. Method: The study included 50 infertile men and 50 young volunteers from the general Iraqi population. Blood samples were drawn from all included men, and semen samples were collected by masturbation. All the samples of semen were investigated for CYP24A1 expression, and routine semen analysis was performed. In addition, the serum was separated and used to assess other biochemical parameters, namely catalase, reactive oxygen species, and vitamin E, which were measured by ELISA. Results: Serum ROS levels were higher in patients than control groups, while the serum catalase and vitamin E levels were significantly lower in patients than controls. CYP24A1 gene expression is significantly higher in infertile men with sperm count higher than 70 million and reaches twofold times the control. Conclusion: CYP24A1 gene expression is significantly higher in infertile men and can be used as a marker of infertility, especially in infertile males with normal sperm count. At the same time, the serum catalase and vitamin E levels were significantly lower, which can be added as tools to predict male infertility..

8.
Rev Bras Ginecol Obstet ; 44(9): 854-865, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35817081

RESUMO

OBJECTIVE: To comparatively evaluate the outcome of treatment with 150 versus 200 units (U) of botulinum toxin in achieving pain-free intercourse and relieving muscle contraction in order to allow gynecological examination. METHODS: In this comparative prospective observational study, 99 patients with vaginismus were treated with botulinum toxin injections from September 2016 to August 2021. Diagnosis and grading of vaginismus severity were assessed using a Female Sexual Function Index (FSFI) questionnaire. Under local or general anesthesia, botulinum toxin diluted with preservative-free saline (150 U and 200 U) was injected into, above, and below the right and left bulbospongiosus muscle and the lateral submucosal areas of the introitus and perineal body using an insulin syringe. Patients were recalled after 2 weeks, and the postoperative outcome was recorded using a similar preoperative questionnaire. RESULTS: Overall, the mean age of patients was 30.2 years. The baseline and clinical characteristics were comparable between the 2 groups (p > 0.05). Significant improvements were seen in the pain and anxiety scores of finger penetration, dilator use, intercourse, and cotton swab in individual groups. The intergroup comparisons between 150 U and 200 U of Botox were not statistically significant (p > 0.05). CONCLUSION: Low-dose Botox (150 U) is equally effective as high dose Botox injections (200 U) in vaginismus patients. Therefore, Botox-150 U can be used to treat vaginismus as an alternative to high doses of the same substance.


OBJETIVO: Avaliar comparativamente o resultado do tratamento com 150 versus 200 unidades (U) de toxina botulínica na obtenção de relações sexuais sem dor e no alívio da contração muscular para permitir o exame ginecológico. MéTODOS: Neste estudo observacional prospectivo comparativo, 99 pacientes com vaginismo foram tratadas com injeções de toxina botulínica de setembro de 2016 a agosto de 2021. O diagnóstico e a classificação da gravidade do vaginismo foram avaliados usando um questionário Female Sexual Function Index (FSFI). Sob anestesia local ou geral, injetou-se toxina botulínica diluída em soro fisiológico sem conservantes (150 U e 200 U) nos músculos bulbo esponjoso direito e esquerdo e nas áreas submucosas laterais do intróito e corpo perineal, utilizando-se uma seringa de insulina. Os pacientes foram chamados após 2 semanas, e o resultado pós-operatório foi registrado usando um questionário pré-operatório semelhante. RESULTADOS: No geral, a média de idade dos pacientes foi de 30,2 anos. As características basais e clínicas foram comparáveis entre os 2 grupos (p > 0,05). Melhorias significativas foram observadas nos escores de dor e ansiedade à penetração com dedo, uso de dilatador, relação sexual e cotonete em grupos individuais. As comparações intergrupos entre 150 U e 200 U Botox foram não estatisticamente significativas (p > 0,05). CONCLUSãO: Botox de baixa dose (150 U) é tão eficaz quanto injeções de Botox de alta dose (200 U) em pacientes com vaginismo. Portanto, o Botox-150 U pode ser usado para tratar o vaginismo como alternativa às altas doses da mesma substância.


Assuntos
Toxinas Botulínicas Tipo A , Dispareunia , Insulinas , Vaginismo , Adulto , Toxinas Botulínicas Tipo A/uso terapêutico , Coito , Dispareunia/tratamento farmacológico , Feminino , Humanos , Insulinas/uso terapêutico , Resultado do Tratamento , Vaginismo/tratamento farmacológico
9.
J Pak Med Assoc ; 71(Suppl 9)(12): S86-S88, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35130249

RESUMO

Bartholin gland carcinomas are rare types of tumours, accounting for less than 1% among females. This case report is of a 20-years patient in her 16th week of pregnancy who presented with pain and swelling in the left groin for two weeks. Examination showed a well-defined fixed swelling with induration in the left vulva, with an irregular margin and a diameter of about 5 cm, just at the Bartholin's gland site with two palpable ipsilateral lymph nodes. Bartholin's gland abscess was suspected. The decision was to drain the pus under general anaesthesia. During the procedure, a hard mass was felt at the left Bartholin glands region. The incision was extended, which unraveled a 5*5 cm abnormal-looking mass; it was hard and fixed to the adjacent tissues. Histopathology confirmed adenocarcinoma of Bartholin gland in stage III. The oncologist advised pregnancy termination and chemoradiation. Although surgical excision is essential for treating tumours, still, a multimodal approach can prove to be more effective.


Assuntos
Adenocarcinoma , Glândulas Vestibulares Maiores , Neoplasias Vulvares , Abscesso , Drenagem , Feminino , Humanos , Gravidez , Neoplasias Vulvares/cirurgia
10.
J Pak Med Assoc ; 69(Suppl 3)(8): S68-S72, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31603881

RESUMO

OBJECTIVE: To evaluate the prevalence and management strategies of placenta accreta spectrum disorders at a tertiary teaching hospital. METHODS: The retrospective cross-sectional study was conducted at Al-Yarmouk Teaching Hospital, Baghdad, Iraq, and comprised record of patients diagnosed with placenta accreta spectrum disorders between January 2014and December 2017. Different management approached employes were noted and data was analysed using SPSS 22. RESULTS: Of the 7312 deliveries during the four-year period, there were 102(1.4%) cases of placenta accreta spectrum disorders. Of them, 83(81.3%) were managed by definitive surgery and 19(18.7%) with conservative surgery. The prevalence of placenta accreta spectrum disorders was 162.4 per 100,000 women in 2014, 266.7 in 2015, 382.3 in 2016, and 191.5 per 100 000 women in 2017. All the cases related to multiparous women with previous history of caesarean section. CONCLUSIONS: The incidence of placenta accreta spectrum disorders was high in our centre.


Assuntos
Placenta Acreta/epidemiologia , Placenta Acreta/cirurgia , Cesárea/estatística & dados numéricos , Estudos Transversais , Feminino , Humanos , Iraque/epidemiologia , Morbidade , Paridade , Guias de Prática Clínica como Assunto , Gravidez , Estudos Retrospectivos , Fatores de Risco , Útero/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...